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2Abstract
Background and objectives Infections are the most common non-cardiovascular causes of death
after kidney transplantation. We analyzed the current infection-related mortality among kidney
transplant recipients in a nationwide cohort in Finland.
Design, setting, participants, and measurements Altogether 3249 adult recipients of a first kidney
transplant during 1990-2012 were included. Infectious causes of death were analyzed and the
mortality rates for infections were compared between two eras (1990-1999 and 2000-2012). Risk
factors for infectious deaths were analyzed with Cox regression and competing risk analyses.
Results Altogether 953 patients (29%) died during the follow-up, with 204 infection-related deaths.
Mortality rate (per 1000 patient-years) due to infections was lower in the more recent cohort (4.6,
95% CI 3.5–6.1) compared to the older cohort (9.1, 95% CI 7.6–10.7); the incidence rate ratio of
infectious mortality was 0.51 (95% CI 0.30–0.68).
The main causes of infectious deaths were common bacterial infections: septicaemia in 38% and
pulmonary infections in 45%. Viral or fungal infections caused only 2% and 3% of infectious deaths
(such as individual cases of Cytomegalovirus pneumonia, Herpes simplex virus
meningoencephalitis, Varicella zoster virus encephalitis and Pneumocystis jirovecii infection).
Similarly, opportunistic bacterial infections rarely caused death; only one death was caused by
Listeria monocytogenes and two by Mycobacterium tuberculosis. Only 23 (11%) of infection-related
deaths occurred during the first posttransplant year. Older recipient age, higher plasma creatinine
concentration at the end of the first posttransplant year diabetes as a cause of end-stage renal
disease, longer pretransplant dialysis duration, acute rejection, low albumin-level, and earlier era of
transplantation were associated with increased risk of infectious death in multivariable analysis.
Conclusions The risk of death due to infectious causes after kidney transplantation in Finland
dropped by half since the 1990s. Common bacterial infections remained the most frequent cause of
infection-related mortality, whereas opportunistic viral, fungal or unconventional bacterial infections
rarely caused deaths after kidney transplantation.
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Introduction
Patient survival after kidney transplantation has improved markedly during the past decades (1, 2).
The frequency of acute rejection has decreased, whereas infectious concerns have increased, and
infections remain the most common non-cardiovascular causes of death after kidney
transplantation accounting for approximately 15–20% of deaths (3-5).
Due to improved diagnostic tools and antiviral agents, common opportunistic viruses such as
Cytomegalovirus (CMV) and BK polyomavirus rarely cause life-threatening infections or graft
losses (6, 7). On the other hand, new infectious threats have emerged such as influenza,
especially influenza A (H1N1) (8), and currently deaths from bacterial infections predominate the
infectious causes of deaths after kidney transplantation (9).
Despite being highly increased after kidney transplantation, little is known about the current
infection-related mortality after kidney transplantation, especially about the specific infectious
causes of death.
The aim of this study is to present current nationwide data on infection-related mortality among
kidney transplant recipients in a modern developed country. We furthermore looked into the risk
factors for infection-related mortality and specific causes of deaths, and evaluated whether these
have changed during the past decades.
4Material and methods
Data collection
All adult recipients of a primary kidney transplantation between 1990 and 2012 (N=3249) in Finland
were included in this observational inception cohort study. During 1990 and 2012, altogether 41
patients received a combined transplant (11 pancreas-kidney and 30 liver-kidney transplants) and
were included in the analyses. Data were retrieved from the Finnish Registry for Kidney Diseases,
which has been estimated to cover 97% to 99% of all patients accepted for renal replacement
therapy (RRT, dialysis or kidney transplantation) in Finland since 1965. All patients have provided
written informed consent and permission to use the data anonymously in registry reports and for
research purposes. Following data were obtained from the registry for all patients at the start of
RRT: age, gender, cause of ESRD as International Classification of Diseases -10 (ICD-10) codes,
date of start of first renal replacement therapy (RRT), initial and last modality of RRT before
transplantation (hemodialysis or peritoneal dialysis), date of first kidney transplantation, date of
return to dialysis after transplantation, date of death (also after transplantation) and cause of death.
Primary kidney disease was categorized as glomerulonephritis, polycystic kidney disease, diabetes
mellitus type 1 or type 2, pyelonephritis, amyloidosis, nephrosclerosis, miscellaneous, or unknown.
Data on body mass index (BMI) and laboratory data from the end of the year before transplantation
and from the end of the first year after transplantation and data about immunosuppression were
available since 1992. Patients with missing data were excluded from the analyses. For laboratory
data and BMI, sensitivity analyses were performed including patients with the data available. Data
about creatinine were missing from 288 patients, and data about plasma albumin were missing
from 678 patients. Patients with missing data were excluded from the analyses. In addition, to
address potential source of bias, data about acute rejections and induction therapy were retrieved
from the Finnish Transplant Registry, and sensitivity analyses were performed including these
data.
Causes of death are reported to the Finnish Registry for Kidney Diseases by the treating
nephrologist. The statistics on mortality in Finland are based on death certificates, in which ICD
5codes for the cause of death are assigned by the physician who treated the deceased during the
final illness. In addition, all death certificates in Finland are submitted for verification to a forensic
medicine specialist in the competent authority, and after approval sent to the official National Death
Register at the Statistics Finland.
If the cause of death was not reported to the Finnish Registry for Kidney Diseases, it was acquired
from Statistics Finland based on the individual social security code. Since 1996, causes of death
statistics have been compiled according to the 10th revision of the ICD code (ICD-10). Before
1996, ICD-9 was used, and these were converted to ICD-10. There were no missing causes of
death.
Causes of death were grouped into four categories: infection, cardiovascular, malignancy and
other.  Causes of infection-related deaths were classified into seven categories: bacterial or
unspecified septicemia (ICD-10 codes A04.7–A49.9), pulmonary infection defined as bacterial or
unspecified pneumonia (J13–J16, J18–J20, J40,J69) or empyema/pleural effusion, specified viral
infection (B25.0, G05.1, J17.1), specified fungal infection (B37.7, B59, J17.2), gastroenterological
infection (K65–K81), tuberculosis (A15.9) and other infection (I33.0, G00.8, I52.0*A39.5, L03.1,
N39.0 M86.1, T87.4).
Statistical Analyses
Comparisons between the groups were performed using Mann-Whitney U test for continuous
variables and the x2–test for categorical variables. Nonparametric statistics were applied, as all
distributions were not normal. Survival probabilities were estimated using the Kaplan-Meier method
with death as the event and patients were censored at the end of the follow-up.  Cause-specific
mortality rates were reported per 1000 person-years (py) and calculated separately for deaths due
to infections, cardiovascular causes, malignancies and due to other causes. Incidence rate ratios
(IRR) were calculated to compare mortality in patients transplanted during the two different eras.
Confidence intervals were calculated according to the Poisson Exact method.
6Cox regression models were used to identify risk factors for infection-related mortality, such as age
at transplantation, gender, cause of end stage renal disease, era of transplantation, initial modality
of pretransplant dialysis, dialysis duration before transplantation and immunosuppressive therapy.
Cause of end stage renal disease was categorized as glomerulonephritis, polycystic kidney
disease, diabetes including both type 1 and type 2 diabetes, and other. Variables that were
significant in univariable model (<0.05) were selected to multivariable models. Cumulative
incidence of death due to infectious causes was calculated using a competing risk method that
takes death due to other causes into account as competing risk events. As an alternative to Cox
regression, relative risks of death due to infection were also estimated fitting a proportional
subdistribution hazards regression model that takes death due to other causes into account as
competing risk events (10, 11). First-degree interactions between all the exposure variables were
analyzed, and all statistically significant interactions are reported. For statistical analyses we used
IBM SPSS Statistics (version 22.0) and the R statistical software 2.14.2 (The R Foundation for
Statistical Computing, Vienna, Austria, http://www.r-project.org). Two-sided P-values less than 0.05
were considered statistically significant.
Results
Study Population
A total of 3249 adult patients (aged => 18) received their first kidney transplantation in Finland
between 1990 and 2012, 1283 during 1990–1999 and 1966 during 2000–2012.  The patients were
followed for a maximum of 22 years from the day of first transplantation until death (N=953) – also
after graft loss – or the end of follow-up period on 31 December 2012, or loss to follow-up (N=12).
The median follow-up time was 14.1 years for patients transplanted during 1990–1999 and 5.7
years for patients transplanted in 2000–2012.
Patients included in the study are described in Table 1. Compared to the patients transplanted
during 1990–1999 the patients transplanted during 2000–2012 were significantly older, had more
often type 2 diabetes as cause of ESRD, were less frequently on peritoneal dialysis and had longer
7duration of dialysis before transplantation.  There were significant differences in the
immunosuppressive regimen between the two decades as tacrolimus and mycophenolate mofetil
were not available during the earlier era. During the recent era all patients with data available on
immunosuppression received either cyclosporine- or tacrolimus-based immunosuppression at
baseline.
Mortality by cause of death
953 (29%) patients died during the follow-up.  204 patients (21% of all deceased patients) died due
to infections, 442 (48%) due to cardiovascular causes, 129 (13%) due to malignancies, and 178
(19%) from other causes. During the most recent vs. the earlier cohort the cause of death was
infectious in 18% vs. 23%, cardiovascular disease in 48% vs. 45% and malignancy in 16% vs.
12%. Altogether 710 (76% of all deceased patients) patients died with a functioning graft.
The overall patient survival in the whole study population was 97% at one year, 89% at 5 years
and 73% at 10 years after transplantation.
Mortality due to infections, cardiovascular causes and malignancies was lower in the recent cohort
(Table 2). The mortality rate (per 1000 patient-years) due to infections was 4.6 vs. 9.1 for patients
transplanted in 2000–2012 vs. 1990–1999 with a mortality rate ratio of 0.51. The mortality rate ratio
was 0.67 for CVD mortality and 0.80 for mortality due to malignancies.
Infection-related mortality and its causes
A total of 204 (21% of all deaths) infection-related deaths occurred during the follow-up of which
147 (72%) among patients with a functioning graft.  Cumulative incidence of infection related-death
was lower in 2000-2012 than in 1990-1999 (Figure 1). During both eras, the most frequent causes
of infectious death were common bacterial infections: pulmonary infection in 45% (36% vs. 49%
during 2000–2012 vs. 1990–1999) and septicemia in 38% (42% vs. 37%) of the cases (Table 3,
supplementary table 1).
8Bacteremia caused 78 deaths of which 31 (40%) were described as unspecified septicemia, while
the causative pathogen was known in 43 (55%) of the cases. Staphylococcus aureus accounted
for 11 and unspecified Gram-negative sepsis for 8 of the bacteremia deaths while there were only
individual cases of Meningococceal and Streptococcal septicemia.  Invasive viral or fungal
infections comprised 2% and 3% of all infectious deaths. Only individual cases of fatal
Cytomegalovirus (CMV) pneumonia, Herpes simplex virus (HSV) meningoencephalitis, Varicella
zoster virus (VZV) encephalitis and Pneumocystis jirovecii infection occurred. Opportunistic
bacterial infections rarely caused death; only one death was caused by Listeria monocytogenes.
Two deaths were caused by Mycobacterium tuberculosis.
Mortality within the first year after kidney transplantation
Of all deaths 83 (9%) occurred within the first year after transplantation. The cause of death was
cardiovascular in 59% vs. 49%, infection in 21% vs. 33%, and malignancy in 6% vs. 10% during the
recent vs. the earlier cohort.  During the first year after transplantation, mortality rate due to infections
was significantly lower in 2000-2012 (3.7 per 1000 py, 95% CI 1.8–7.9) than in 1990-1999 (12.8 per
1000 py, 95% CI 7.8–21.0) with a mortality rate ratio of 0.29 (95% CI 0.12–0.71).
Of the 23 infection-related deaths that occurred during the first year after transplantation, the cause
was septicemia in 44% and pulmonary infection in 30%. There were only one cytomegalovirus-
related death and individual cases of HSV-meningoencephalitis and viral pneumonia as a cause of
death during the first year after transplantation.
Infection-related mortality risk factors
Older age was the strongest predictor of infection-related mortality. When adjusting for age and
gender, earlier era of transplantation (HR=1.78, 95% CI 1.25-2.53), diabetes as the cause of
ESRD (HR=1.78, 95% CI 1.21-2.62), and dialysis duration for more than two years before
transplantation (HR=1.59, 95% CI 1.12-2.25) were associated with infection-related death (Table
4).
9Laboratory data from the end of the calendar year of the transplantation were available for 91% of
the patients on plasma creatinine and for 79% on plasma albumin. When adjustment was made for
age and gender, higher plasma creatinine (HR=1.001 per 1 μmol/l increment, 95% CI 1.000-1.002,
p= 0.002) and plasma albumin level below 36 g/l (HR=1.58, 95% CI 1.13-2.23, p =0.008). were
associated with risk of infection-related mortality.
During the recent era, the risk of death from infection was almost twofold in men, whereas this was
not the case in the earlier era (Table 4). The association of diabetes as the cause of ESRD or
pretransplant dialysis duration with infection-related mortality lost statistical significance during the
recent era, but no interaction was observed between diabetes or dialysis duration and era with
respect the risk of infectious death (p=0.18).
Sensitivity analyses
A separate analysis that included as events only infection-related deaths of patients with a
functioning graft showed similar hazard ratios for the risk factors as in Table 4 (table S2).
As an alternative method of analysis, competing risk models were built on the whole study
population using death due to infection as the primary outcome, and death resulting from
cardiovascular causes, malignancies and other causes as competing risk events. These models
showed no important differences compared to the Cox regression models presented in Table 4
(table S3).
Data about acute rejections or induction immunosuppression were available for 88% of the patients
transplanted between 1990-2012. Frequency of acute rejection was 13 % among patients
transplanted in 2000-2012 vs. 23% among patients transplanted in 1990-1999 (P<0.001). When
included in the Cox regression model analyzing the risk of infectious mortality (adjusted for patient
age, gender, era of transplantation, cause of ESRD, pretransplant dialysis duration), acute
rejection was independently associated with an increased risk of infectious death (HR=1.66, 95%
CI 1.20-2.30, P=0.002). There was a significant interaction between the era of transplantation and
acute rejection with regard to the risk of infectious death (P=0.02). Acute rejection lost statistical
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significance during the most recent era (P=0.36), whereas among patients transplanted in 1990-
1999, acute rejection was associated with increased risk of infectious death (HR=1.92, 95% CI
1.35-2.74, P<0.001).
Induction with ATG was given to 1.6% of patients transplanted in 1990-1999 and to 2.6% of
patients transplanted in 2000-2012, and induction with basiliximab was given to 7.3% of patients
transplanted in 2000-2012 (basiliximab not available in the 1990s). Induction was not associated
with increased infectious mortality risk after transplantation (HR=0.80, 95% CI 0.41-1.57, p=0.52,
adjusted for age and gender).
Discussion
Our current study shows that patient survival after kidney transplantation in Finland has improved
and the risk of death from all causes has decreased. Additionally, the risk of death due to infectious
causes is lower in the recent in comparison to the historic cohort. This is in line with a recent ERA-
EDTA Registry report showing that the risk of cardiovascular and infectious death has fallen by
29% and 8% between 1998–2002 and 2003–2007 (12). All-cause and infection-related mortality
have decreased in spite of transplanting older recipients with increasing degree of comorbidity,
longer pretranplant dialysis duration, more powerful immunosuppressive therapy, and also the
increased use of marginal donors. The incidence of acute rejection has decreased between the
two eras in our cohort, and acute rejection was an independent risk factor for infectious death only
in patients transplanted in the 1990s, suggesting that lower frequency of acute rejection and
especially the treatment of acute rejection is the most important factor explaining the reduced
infectious mortality in our cohort. In addition, better and faster diagnostic tools for infections
together with increased awareness of severe opportunistic infections may have contributed to the
reduced infectious mortality.
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The particular causes of death among kidney transplant recipients have changed over time.
Infections were the most common cause of death in the early years of transplantation (42% in 1980
to 1989 and decreasing to 28% in 1990 to 1999) (3). According to the United States Renal Data
System Annual Data Report 2012 33% of the known death causes among transplant patients were
cardiovascular while infections accounted for 18% of  deaths (4). Notably, the cause of death was
missing or unknown for 68% of these transplant patients. The UK Renal registry has demonstrated
a marked decrease in the proportion of cardiovascular deaths among all renal replacement therapy
patients (from 34% in 2000 to 22% in 2011), but a similar trend was not observed for infection-
related mortality, which has remained stable at approximately 18% of all mortality. Among
transplant patients infection was responsible for 23% and cardiovascular disease for 18% of the
deaths (5). Compared to the general population kidney transplant recipients have a 32-fold risk of
dying of infection, and the risk is particularly emphasized in young women (13). In kidney
transplant recipients the mortality secondary to septicemia is 20-fold and the mortality secondary to
pulmonary infection is 2-fold compared to the general population (14, 15).
Although the incidence of fatal infections after kidney transplantation has decreased over time,
studies assessing infectious mortality are scarce and current information on specific infectious
causes of death following kidney transplantation has not been available. In our current analysis
common bacterial infections remain the most frequent cause of infection-related mortality, whereas
viral, fungal or unconventional bacterial infections rarely caused deaths after kidney
transplantation. It is well known that the spectrum of infections after transplantation varies over
time. Early infections during the first month after transplantation are likely to be nosocomial
bacterial infections. Opportunistic pathogens occur during the following five months as a result of
the high level of immunosuppression, and later infections are either opportunistic infections or
conventional ones (16, 17). Accoding to USRDS 2003 annual report 70% of all kidney transplant
recipient will experience an infection episode by three years after transplantation and
hospitalization for bacterial infections after kidney transplantation is roughly twice as common as
hospitalization for viral infections despite much greater attention to posttransplant viral infections in
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the published literature (18), and infections may be a more common reason for hospitalization after
transplantation than acute rejections (19). According to a recent registry analysis among the
deceased kidney transplant recipients, in whom the causative infectious agent was known, 85%
died of bacterial infections whereas only 9% died of viral infections and 6% of other types of
infections (13).
Interestingly, most fatal infections occurred late after transplantation. Mortality rate of infection
within one year from transplantation was not higher compared to later follow-up. Of the 3249
transplant patients in this study only 2.6% died within the first year after transplantation. Infections
accounted for 28% of all deaths during the first year while cardiovascular disease was the most
common cause of death. This is in contrast with previous studies reporting that within the first year
after transplantation infections are the leading cause of death (20, 21). The risk of death from
infections has declined which may have contributed to the improvement in the 1-year survival rate
after kidney transplantation. As the survival of transplant patients improve, long-term complications
of immunosuppression, such as malignancies, raise increased concern and cancer-related deaths
may replace infections as causes of death. In our current study, however, both all-cause and
cancer related mortality rate was smaller in the more recent cohort compared to the older cohort.
The low incidence of viral- and fungal-related deaths even in the first year after transplantation was
somewhat surprising. Only one patient died because of CMV-infection. CMV is the most common
viral infection after kidney transplantation affecting 10–19% of recipients receiving conventional
immunosuppressive therapy, but serious disease caused by CMV is rare (6). Antiviral prophylaxis in
the highest-risk (D+/R-) population has reduced the incidence of CMV disease by 60% which has
contributed to the reduced all-cause mortality (22). Data about donor or recipient serostatus were
unfortunately not available for the current study. Similarly, only one patient died due to Pneumocystis
jirovecii (PJP), arguing either for successful use of prophylaxis in our cohort, or on the other hand
that the incidence of PJP is very low, calling into question the wisdom of extensive prophylaxis with
trimethoprim, which is also associated with toxicity and concerns about antimicrobial resistance.
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Specific data for infection prophylaxis were not available for the purpose of this study. However,
according to the policy in our country, only prophylaxis against pneumocystis jirovecii for the first
six months after transplantation with either trimethoprim-sulfamethoxazole or pentamidine
inhalations was given. Other infection prophylaxis was not routinely used, with the exception of six
months valganciclovir prophylaxis for CMV seronegative recipients of a kidney from a seropositive
donor initiated in 2004. Our study cohort may also otherwise differ from other kidney transplant
cohorts, especially with regard to almost exclusively Caucasian population in Finland, the high
frequency of cyclosporine use, and low frequency of induction therapy, and therefore our findings
may not be directly applicable to other cohorts.
Our study has a few limitations. Death certificates may have limitations in their quality. The Finnish
Registry for Kidney Diseases allows only one cause of death to be reported and some patients
may have had several factors leading to death. On the other hand, kidney transplant recipients are
under continuous medical follow-up and the causes of death were reported by the treating
nephrologist and are the best available data. Earlier Finnish studies have verified the validity and
good quality of Finnish death certificates, death certification practices, and the cause of death
validation procedures producing the register data on mortality, justifying their use for endpoint
assessment in epidemiological studies (23-25). In addition, no standardized definition of infectious
death exists in the registry or in the death certificates, e.g. with regard to the microbiological or
radiological diagnosis of the infection or timing of death in relation to the infectious diagnosis, but is
only based on the evaluation of the treating physician, which limits the accuracy of our data.
Another limitation is that this study focused only on infectious causes of death, and no data were
available about non-fatal infections, which also cause substantial morbidity after kidney
transplantation. In addition, although some speculations about the reduced risk of infectious deaths
can be made with regard to lower incidence of acute rejections in the most recent cohort, our study
is limited by the inability to determine with confidence the mechanisms behind the reduced
infectious mortality seen between the eras.
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In accordance with earlier studies among immunocompromised patients, pulmonary infections
remain a major cause of death (26). Pulmonary infection was responsible for most (45%) deaths
from infection and in 55% of these cases the cause of death was unspecified pneumonia (J18.9).
Septicemia accounted for over a third of infectious deaths and information on the sites of infection
or the defined pathogen associated with septicemia was not available in 40% of these cases. This
is in accordance with the fact that a pathogen can be identified by blood culture in no more than
30- 40% of patients with sepsis (27). In addition to microbiological criteria, clinical criteria have
provided the basis for epidemiological studies of sepsis since the 1990s (28, 29) and clinical sepsis
codes have been included in ICD-10 since 2005. In addition, conversion from the older ICD 9
codes to ICD 10 codes may explain some inaccuracy in the diagnoses.
On the other hand the key strength of this study is the virtually complete coverage of kidney
transplantations in Finland with complete follow-up data of a large representative national cohort
allowing us to compare mortality in different eras of transplantation. Data about the cause of death
were available for all patients included in this study – no deaths were coded as unknown or
missing, which minimizes selection bias.
In conclusion, the survival after kidney transplantation in Finland continues to improve. The risk of
death due to infections after kidney transplantation has dropped by half since the 1990s. Common
bacterial infections remain the most frequent cause of infection-related mortality, whereas
opportunistic viral, fungal or unconventional bacterial infections rarely cause deaths after kidney
transplantation.
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Table 1. Baseline characteristics of first kidney transplant recipients enrolled in the Finnish
Registry for Kidney Diseases (N=3249).
Variables All 1990-99, n=1283 2000-12, n=1966
Men, % 2041 (63) 778 (61) 1263 (64)
Age (yr) at transplantation 49±13 45±12 51±13
Age group at
transplantation,%
  18-44
  45-65
  over 65
1233 (38)
1690 (52)
326 (10)
606 (47)
606 (47)
71 (6)
627 (32)
1084 (55)
255 (13)
Treatment before
transplantion
  Hemodialysis
  Peritoneal dialysis
  Pre-emptive
1936 (60)
1300 (40)
13 (0.4)
716 (56)
562 (44)
5 (0.4)
1220 (62)
738 (38)
8 (0.4)
Time (yr) on dialysis prior
to transplantation
1.8±1.6 1.4±1.3 2.1±1.7
Cause of ESRD, %
  Glomerulonephritis
  Polycystic disease
  Diabetes type 1
  Diabetes type 2
  Chronic pyelonephritis
  Amyloidosis
 Nephrosclerosis
 Other
 Unknown
769 (24)
591 (18)
786 (24)
143 (5 )
214 (7)
76 (2)
101 (3)
366 (11)
203  (6)
343 (27)
208 (16)
327 (26)
25 (2)
107 (8)
40 (3)
39 (3)
147 (11)
47 (4)
426 (22)
383 (20)
459 (23)
118 (6)
107 (5)
36 (2)
62 (3)
219 (11)
156 (8)
Immunosuppression, %
Cyclosporine
Tacrolimus
Mycophenolate mofetil
Steroid
Azathioprine
Missing
906 (71)
0
94 (7)
963 (75)
806 (63)
308 (24)
1452 (74)
407 (21)
1524 (78)
1697 (86)
201 (10)
98 (5)
Mean ± standard deviation unless otherwise indicated.
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Table 2.
Mortality rates (deaths/1000 patient years) and mortality rate ratios from all causes, cardiovascular
causes, malignancy and infections in first kidney transplant recipients in Finland segregated by the
era of transplantation, IRR=incidence rate ratio.
Cause of mortality 1990-1999 (95%CI) 2000-2012 (95%CI) IRR 95% CI
All-cause 39.8 (37.0-43.1)
(n=666)
24.9 (22.2-28.0)
(n=287)
0.63 0.55-0.72
Infection 9.1 (7.6-10.7)
(n=151)
4.6 (3.0-5.4)
(n=53)
0.51 0.30-0.68
1-year Infectious
mortality
12.8 (7.81-20.98)
(n=16)
3.7 (1.78-7.86)
(n=7)
0.29 0.12-0.71
Cardiovascular 18.2 (16.0-20.7)
(n=303)
12.1 (10.2-14.4)
(n=139)
0.67 0.56-0.76
Malignancy 5.0 (4.0-6.2)
(n=83)
4.0 (3.0-5.4)
(n=46)
0.80 0.63-0.95
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Table 3.
Infectious causes of death after kidney transplantation among first kidney transplant recipients
enrolled in the Finnish Registry for Kidney Diseases (N=3249).
Type of infection All
(n=204)
1990-1999
(n=151)
2000-2012
(n=53)
Pulmonary infection,% 92 (45) 73 (48) 19 (36)
Septicemia,% 78 (38) 56 (37) 22 (42)
Gastroenteric infection,% 12 (6) 9 (6) 3 (6)
Fungal infection,% 6 (3) 3 (2) 3 (6)
Viral infection,% 4 (2) 1 (1) 3 (6)
Tuberculosis,% 2 (1) 1 (1) 1 (1)
Other,% 10 (5) 8 (5) 2 (3)
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Table 4.
Risk factors for infectious death among first kidney transplant recipients enrolled in the
Finnish Registry for Kidney Diseases.
A) All patients (N=3249)
Adjusted * HR (95%CI) Adjusted ** HR(95% CI) Number of
infectious
deaths
Age (per 1-year
increment)
1.06 (1.04-1.07), p<0.001 1.07 (1.05-1.08), p<0.001 204
Sex
Men
Women
1.20 (0.90-1.59)
1
1.13 (0.85-1.52)
1
131
73
Era of
transplantation
1990-1999
2000-2012
1.78 (1.25-2.53), p=0.002
1
2.07 (1.44-2.98), p<0.001
1
151
53
Cause of end stage
renal disease
Glomerulonephritis
Polycystic kidney
disease
Diabetes
Other
1
0.78 (0.51-1.20)
1.78 (1.21-2.62), p=0.003
0.90 (0.61-1.31)
1
0.83 (0.54-1.28)
1.89 (1.28-2.79), p=0.001
0.90 (0.61-1.32)
52
36
60
56
Pretransplant
dialysis duration
0-12 mo
12-24 mo
>24 mo
1
1.39 (1.00-1.94), p=0.05
1.59 (1.12-2.25), p=0.009
1
1.41 (1.01-1.97), p=0.04
1.75 (1.23-2.50), p=0.002
72
70
62
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* Adjusted for patient age and gender. ** Adjusted for patient age, gender, era of
transplantation, cause of ESRD, and dialysis duration. *** Adjusted for patient age, gender,
cause of ESRD, and dialysis duration
B) Patients transplanted 1990-1999 (N=1283)
Adjusted * RR (95%CI) Adjusted *** RR(95% CI) Number of
infectious
deaths
Age (per 1-year
increment)
1.05  (1.03-1.06), p<0.001 1.06 (1.04-1.08), p<0.001 151
Sex
Men
Women
1.05 (0.76-1.45)
1
1.0 (0.72-1.39)
1
91
60
Cause of end stage
renal disease
Glomerulonephritis
Polycystic kidney
disease
Diabetes
Other
1
0.81 (0.49-1.33)
2.01 (1.29-3.14), p=0.002
0.86 (0.55-1.35)
1
0.85 (0.51-1.40)
2.03 (1.30-3.18) p=0.002
0.83 (0.53-1.30)
40
26
46
39
Pretransplant
dialysis duration
0-12 mo
12-24 mo
>24 mo
1
1.57 (1.08-2.27), p=0.018
1.80 (1.08-2.99), p=0.004
1
1.51 (1.04-2.19), p=0.029
1.90 (1.26-2.87) p=0.002
60
53
38
C) Patients transplanted 2000-2012 (N=1966)
Adjusted * RR (95%CI) Adjusted *** RR(95% CI)
Age (per 1-year
increment)
1.10 (1.07-1.135),
p<0.001
1.11 (1.07-1.14), p<0.001 53
Sex
Men
Women
1.92 (1.03-3.60), p=0.04
1
1.81 (0.96-3.41) p=0.68
1
40
13
Cause of end stage
renal disease
Glomerulonephritis
Polycystic kidney
disease
Diabetes
Other
1
0.86 (0.37-2.00)
1.64 [0.74-3.62), p=0.22
1.04 (0.49-2.2)
1
0.85 (0.37-2.00)
1.58 (0.71-3.51)
1.02 (0.48-2.14)
12
10
14
17
Pretransplant
dialysis duration
0-12 mo
12-24 mo
>24 mo
1
1.09 (0.52-2.30)
1.38 (0.68-2.79)
1
1.03 (0.49-2.17)
1.28 (0.62-2.62)
12
17
24
24
Figure Legends
Figure 1. Cumulative probability of infectious death in transplant recipients. Continuous line:
years 1990 to 1999, dotted line: years 2000 to 2012.

